vs
Alector, Inc.（ALEC）与Forian Inc.（FORA）财务数据对比。点击上方公司名可切换其他公司
Forian Inc.的季度营收约是Alector, Inc.的1.3倍（$8.0M vs $6.2M），Forian Inc.同比增速更快（37.0% vs -88.5%），过去两年Forian Inc.的营收复合增速更高（27.8% vs -37.4%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
Forian Inc是一家专注于医疗健康领域的数据分析与技术服务商，提供SaaS模式的真实世界证据解决方案、临床决策支持工具及运营优化服务，客户覆盖生物制药企业、医疗机构及生命科学领域相关机构，助力提升诊疗效率、推动医学研究进展。
ALEC vs FORA — 直观对比
营收规模更大
FORA
是对方的1.3倍
$6.2M
营收增速更快
FORA
高出125.5%
-88.5%
两年增速更快
FORA
近两年复合增速
-37.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $8.0M |
| 净利润 | — | $-1.8M |
| 毛利率 | — | 49.2% |
| 营业利润率 | — | -24.4% |
| 净利率 | — | -22.9% |
| 营收同比 | -88.5% | 37.0% |
| 净利润同比 | -1696.9% | -1012.2% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECFORA
| Q4 25 | $6.2M | $8.0M | ||
| Q3 25 | $3.3M | $7.8M | ||
| Q2 25 | $7.9M | $7.5M | ||
| Q1 25 | $3.7M | $7.1M | ||
| Q4 24 | $54.2M | $5.8M | ||
| Q3 24 | $15.3M | $4.7M | ||
| Q2 24 | $15.1M | $4.8M | ||
| Q1 24 | $15.9M | $4.9M |
净利润ALECFORA
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $-34.7M | $-151.2K | ||
| Q2 25 | $-30.5M | $224.8K | ||
| Q1 25 | $-40.5M | $-1.1M | ||
| Q4 24 | $-2.1M | $199.7K | ||
| Q3 24 | $-42.2M | $-204.9K | ||
| Q2 24 | $-38.7M | $-2.6M | ||
| Q1 24 | $-36.1M | $-1.2M |
毛利率ALECFORA
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 51.6% | ||
| Q2 25 | — | 56.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 58.3% | ||
| Q3 24 | — | 70.1% | ||
| Q2 24 | — | 62.2% | ||
| Q1 24 | — | 65.1% |
营业利润率ALECFORA
| Q4 25 | — | -24.4% | ||
| Q3 25 | -1153.6% | -6.1% | ||
| Q2 25 | -433.6% | 0.6% | ||
| Q1 25 | -1216.5% | -19.8% | ||
| Q4 24 | -13.4% | -24.9% | ||
| Q3 24 | -315.7% | -17.0% | ||
| Q2 24 | -302.4% | -62.2% | ||
| Q1 24 | -275.0% | -36.3% |
净利率ALECFORA
| Q4 25 | — | -22.9% | ||
| Q3 25 | -1063.4% | -1.9% | ||
| Q2 25 | -387.7% | 3.0% | ||
| Q1 25 | -1101.6% | -16.0% | ||
| Q4 24 | -3.8% | 3.4% | ||
| Q3 24 | -275.2% | -4.4% | ||
| Q2 24 | -256.4% | -53.4% | ||
| Q1 24 | -227.0% | -24.9% |
每股收益（稀释后）ALECFORA
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-0.34 | $0.00 | ||
| Q2 25 | $-0.30 | $0.01 | ||
| Q1 25 | $-0.41 | $-0.04 | ||
| Q4 24 | $-0.02 | $0.01 | ||
| Q3 24 | $-0.43 | $-0.01 | ||
| Q2 24 | $-0.40 | $-0.08 | ||
| Q1 24 | $-0.38 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $31.6M |
| 总债务越低越好 | $10.0M | — |
| 股东权益账面价值 | $30.6M | $29.8M |
| 总资产 | $293.2M | $44.1M |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALECFORA
| Q4 25 | $256.0M | $31.6M | ||
| Q3 25 | $291.1M | $28.2M | ||
| Q2 25 | $307.3M | $35.6M | ||
| Q1 25 | $354.6M | $35.7M | ||
| Q4 24 | $413.4M | $35.1M | ||
| Q3 24 | $457.2M | $49.4M | ||
| Q2 24 | $503.3M | $48.0M | ||
| Q1 24 | $562.1M | $47.4M |
总债务ALECFORA
| Q4 25 | $10.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALECFORA
| Q4 25 | $30.6M | $29.8M | ||
| Q3 25 | $57.7M | $31.1M | ||
| Q2 25 | $71.2M | $30.9M | ||
| Q1 25 | $94.6M | $30.0M | ||
| Q4 24 | $126.8M | $30.1M | ||
| Q3 24 | $118.9M | $28.4M | ||
| Q2 24 | $150.6M | $27.2M | ||
| Q1 24 | $178.9M | $28.1M |
总资产ALECFORA
| Q4 25 | $293.2M | $44.1M | ||
| Q3 25 | $335.3M | $41.3M | ||
| Q2 25 | $356.4M | $48.5M | ||
| Q1 25 | $408.3M | $48.6M | ||
| Q4 24 | $468.3M | $47.2M | ||
| Q3 24 | $516.0M | $57.5M | ||
| Q2 24 | $570.7M | $58.4M | ||
| Q1 24 | $635.5M | $57.5M |
负债/权益比ALECFORA
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-184.0M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | $-184.1M | — |
| 自由现金流率自由现金流/营收 | -2951.3% | — |
| 资本支出强度资本支出/营收 | 0.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-326.5M | — |
8季度趋势，按日历期对齐
经营现金流ALECFORA
| Q4 25 | $-184.0M | $3.2M | ||
| Q3 25 | $-32.5M | $-439.7K | ||
| Q2 25 | $-49.0M | $-344.5K | ||
| Q1 25 | $-60.8M | $448.2K | ||
| Q4 24 | $-55.0M | $1.7M | ||
| Q3 24 | $-50.7M | $764.1K | ||
| Q2 24 | $-62.8M | $-23.1K | ||
| Q1 24 | $-61.3M | $-2.2M |
自由现金流ALECFORA
| Q4 25 | $-184.1M | — | ||
| Q3 25 | $-32.5M | — | ||
| Q2 25 | $-49.1M | — | ||
| Q1 25 | $-60.8M | — | ||
| Q4 24 | $-55.2M | — | ||
| Q3 24 | $-50.9M | — | ||
| Q2 24 | $-63.1M | — | ||
| Q1 24 | $-61.9M | — |
自由现金流率ALECFORA
| Q4 25 | -2951.3% | — | ||
| Q3 25 | -997.6% | — | ||
| Q2 25 | -623.0% | — | ||
| Q1 25 | -1655.0% | — | ||
| Q4 24 | -101.8% | — | ||
| Q3 24 | -332.1% | — | ||
| Q2 24 | -418.6% | — | ||
| Q1 24 | -389.3% | — |
资本支出强度ALECFORA
| Q4 25 | 0.7% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.3% | 0.0% | ||
| Q3 24 | 1.4% | 0.0% | ||
| Q2 24 | 2.2% | 0.0% | ||
| Q1 24 | 3.4% | 0.0% |
现金转化率ALECFORA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.53× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 8.76× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALEC
暂无分部数据
FORA
| Financial Services Revenues | $7.3M | 92% |
| Other | $669.0K | 8% |
